Old drug, new hope: sirolimus shows promise for rare castleman disease
NCT ID NCT03933904
First seen Mar 14, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tested the drug sirolimus in 7 people with idiopathic multicentric Castleman disease (iMCD) who did not get better with standard therapy. The goal was to see if sirolimus could improve symptoms like fever, fatigue, and weight loss, and shrink swollen lymph nodes. Results will help doctors understand if sirolimus is a useful treatment option for this rare condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.